J6Z-MC-IIBD - A Master Protocol for Phase 2, Randomized, Controlled Studies of Multiple Interventions for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease J6Z-MC-CD01 - A Phase 2, Multicenter, Randomized, Open-Label, Active-Controlled Study to Investigate LY4395089/Mirikizumab Co-administration Compared with Mirikizumab in Adults with Moderately to Severely Active Crohn’s Disease

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524112-11-00

Enrollment

Registered

2026-06-11

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

J6Z-MC-IIBD - Colitis, Ulcerative Crohn Disease J6Z-MC-CD01 - Crohn Disease

Brief summary

J6Z-MC-CD01 - Percentage of Participants with Crohn’s Disease who Achieve Endoscopic Response, J6Z-MC-IIBD - The proportion of participants who achieve the following at Week 12 of Study Period 1: UC: endoscopic improvement CD: endoscopic response

Interventions

DRUGMirikizumab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
J6Z-MC-CD01 - Percentage of Participants with Crohn’s Disease who Achieve Endoscopic Response, J6Z-MC-IIBD - The proportion of participants who achieve the following at Week 12 of Study Period 1: UC: endoscopic improvement CD: endoscopic response	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jun 12, 2026